Puig takes majority stake in Isdin

Announced in mid-September 2026, the definitive share purchase agreement finalizes the complete consolidation of ISDIN by the Spanish conglomerate Puig, structurally transforming the former joint venture into a wholly owned corporate subsidiary. The execution of this major industry buyout involves the acquisition of the remaining fifty percent equity stake previously held by Corporación Químico-Farmacéutica Esteve (CQFE), terminating a historic fifty-year partnership between the Puig and Esteve families. To finalize the transfer of control across the shareholding structure, the acquiring group structures the capitalization via a precise two-tranche payment mechanism: an immediate deployment of nine hundred million euros in cash payable upon the official closing scheduled for the first quarter of 2027, followed by a deferred compensation installment of three hundred million euros (approximately 346 million dollars) guaranteed for the first quarter of 2029. By orchestrating this massive liquidity event, the exiting pharmaceutical holding company led by Chairman Albert Esteve secures substantial institutional capital to systematically reinvest in its legacy pharmaceutical manufacturing and CDMO industrial operations. For the strategic acquirer, this consolidation represents a decisive move to aggressively increase its market share within the highly profitable dermocosmetics market, effectively capturing full operational control of a highly scalable platform without the need to share future dividends. The corporate integration will leverage the buyer's extensive global commercial network to actively expand the acquired brand's international footprint. The newly wholly owned entity will maintain its foundational scientific commitment while benefiting from the parent company's massive operational resources, ensuring long-term continuity for its specialized workforce and dedicated pharmacy distribution networks. This decisive transaction actively bypasses a recently failed attempt by the acquirer to merge with competitor Estée Lauder, forcefully reaffirming the buyer's absolute independence and aggressive appetite for premium clinical assets within the evolving luxury beauty landscape.